Our client distinguished himself in his career as a leader in the field of pharmaceutical biotechnology and biomedical drugs. Attorney Furqan argued that his work had substantial intrinsic merit to the regional and national interest of the United States as it relates to the strain that healthcare costs have on our economy. The NIW was approved without an RFE.
